Stock events for NovoCure Ltd. (NVCR)
NovoCure's stock has experienced volatility over the past six months. As of February 27, 2026, the share price was $13.67, compared to $18.41 on March 3, 2025. Key events include the release of Q4 and full-year 2025 financial results, which showed revenue growth but a net loss. The FDA approved Optune Pax for pancreatic cancer, and Optune Lua received reimbursement approval in Japan for non-small cell lung cancer. Analysts have a consensus "Hold" rating for the stock.
Demand Seasonality affecting NovoCure Ltd.’s stock price
The provided information does not explicitly indicate any significant demand seasonality for NovoCure Ltd.'s products and services. Revenue growth is primarily driven by an increase in active patients on therapy and the expansion into new markets and indications, rather than seasonal fluctuations.
Overview of NovoCure Ltd.’s business
NovoCure Ltd. is an oncology company focused on developing, manufacturing, and commercializing its proprietary platform technology, Tumor Treating Fields (TTFields) devices, for the treatment of solid tumor cancers. The company operates within the Healthcare sector, specifically in the Medical - Instruments & Supplies industry, or more broadly, Medical Devices. NovoCure's major commercialized products include Optune Gio, approved for glioblastoma, Optune Lua, approved for metastatic non-small cell lung cancer and malignant pleural mesothelioma, and Optune Pax, recently approved for locally advanced pancreatic cancer. The company's pipeline also includes ongoing clinical trials investigating TTFields in other cancers.
NVCR’s Geographic footprint
NovoCure Ltd. has a global geographic footprint, deriving the majority of its revenue from the United States. The company also has significant operations and derives revenue from Germany, France, Japan, and Greater China (through a partnership with Zai Lab). As of September 30, 2025, NovoCure had 4,416 active patients globally across its approved indications. The company's global headquarters are located in Baar, Switzerland, with primary operational locations in the USA (Portsmouth, NH, and New York, NY).
NVCR Corporate Image Assessment
NovoCure's brand reputation is centered on its innovative Tumor Treating Fields (TTFields) technology and its commitment to advancing cancer treatment. Regulatory approvals, clinical trial progress, and patient growth contribute to a perception of innovation and future growth potential. Challenges such as slower-than-projected launches and ongoing unprofitability can influence investor perception.
Ownership
NovoCure Ltd. has a mixed ownership structure, with a significant portion held by institutional investors, approximately 83.94% to 84.61%. Major institutional owners include Fmr Llc, BlackRock, Inc., and Vanguard Group Inc. Individual insider ownership accounts for approximately 2.19% to 3.32% of total shares outstanding. William F. Doyle, the Executive Chairman, is the largest individual shareholder, owning 25.21 million shares, representing 22.15% of the company.
